NEGR1: The Search for a Drug Target in the IgLON Family (G257194)

Target Name: NEGR1

NCBI ID: G257194

NEGR1

NEGR1: The Search for a Drug Target in the IgLON Family

The immune system is a vital component of our bodies, responsible for protecting us from external threats such as viruses, bacteria, and diseases. One of the key components of the immune system are the natural killer cells, also known as NK cells. These cells play a critical role in detecting and destroying abnormal cells in the body, including cancer cells. In recent years, researchers have been increasingly interested in the study of the IgLON family member 4 protein, as it has been shown to have potential as a drug target for a variety of diseases.

The IgLON family member 4 protein is a member of the IgLON family, which is a family of proteins that are involved in the regulation of inflammation and immune responses. The IgLON family member 4 protein is a 21-kDa protein that is expressed in various tissues throughout the body, including the brain, spleen, and thymus. It is characterized by a string of 21 amino acid residues that are located at its C-terminus.

One of the key functions of the IgLON family member 4 protein is its role in the regulation of NK cell function. NK cells are a type of natural killer cell that play a critical role in immune surveillance of the body. They are able to detect and destroy abnormal cells in the body, including cancer cells, and are an important part of the immune system.

Research has shown that the IgLON family member 4 protein plays a critical role in the regulation of NK cell function. Studies have shown that the IgLON family member 4 protein is able to inhibit the activity of NK cells, which would normally help to protect the body against cancer. This suggests that the IgLON family member 4 protein may be a potential drug target for cancer treatment.

Another potential function of the IgLON family member 4 protein is its role in the regulation of inflammation. Inflammation is a natural response of the immune system to injury or infection, and it can be a harmful response if it is not controlled. The IgLON family member 4 protein is involved in the regulation of inflammation by controlling the activity of immune cells.

Research has shown that the IgLON family member 4 protein is involved in the regulation of inflammation by controlling the activity of immune cells. Studies have shown that the IgLON family member 4 protein is able to regulate the activity of T cells, which are a type of immune cell that play a critical role in inflammation. This suggests that the IgLON family member 4 protein may be a potential drug target for treating inflammatory diseases.

The IgLON family member 4 protein has also been shown to have potential as a biomarker for a variety of diseases. This is because it is expressed in various tissues throughout the body and can be easily isolated and measured. For example, studies have shown that the IgLON family member 4 protein is often elevated in the blood of people with cancer, and can be used as a biomarker for cancer diagnosis and treatment.

In conclusion, the IgLON family member 4 protein is a promising drug target for a variety of diseases due to its role in the regulation of NK cell function and inflammation. Further research is needed to fully understand the potential of this protein as a drug.

Protein Name: Neuronal Growth Regulator 1

Functions: May be involved in cell-adhesion. May function as a trans-neural growth-promoting factor in regenerative axon sprouting in the mammalian brain (By similarity)

The "NEGR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEGR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets